- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
73 percent Decline in COVID-19 incidences with Prophylactic use of Ivermectin: AIIMS Bhubaneshwar Research
New Delhi: Ivermectin an approved drug of choice in certain parasitic and roundworm diseases has been found to be an effective prophylaxis for COVID 19 as per the a study report by AIIMS, Bhubaneswar. in medRxiv. The study has been published in medRXiv
Ivermectin is one of the many drugs under-study for COVID 19. Now recent research undertaken by the doctors at All India Institute of Medical Sciences, Bhubaneswar (AIIMS Bhubaneswar) has reported a 73% decline in the incidences of COVID-19 cases in healthcare workers who participated in the study
With the raging case of COVID 19 in healthcare workers in AIIMS, Bhubaneswar as many as 20 to 25 cases per day in early September, the current study was conceived and implemented after reviewing the existing literature. The Involvement in the study was purely voluntary. It was a hospital-based matched case-control study with a total of 186 pairs, 77 in control, and 38 in the case group. Cases and controls were healthcare workers who tested positive and negative, respectively, for COVID-19 by RT-PCR. The study took place from September to October. profession gender age and date of the test were matched to avoid errors and selection bias in the study.
Exposure was defined as the intake of ivermectin and/or hydroxychloroquine and/or vitamin-C and/or other prophylaxis for COVID-19. Data collection and entry was done in Epicollect5, and analysis was performed using STATA version 13. Conditional logistic regression models were used to describe the associated factors for COVID-19 infection.
Ivermectin prophylaxis was taken by 77 controls and 38 cases. The authors found that Two-dose ivermectin prophylaxis was associated with 73% reduction of COVID-19 infection among healthcare workers for the following one month, those who were involved in physical activity for more than an hour/day were more likely to contract COVID-19 infection. Type of household, COVID duty, single-dose ivermectin prophylaxis, vitamin-C prophylaxis and hydroxychloroquine prophylaxis were not associated with COVID-19 infection.
The authors concluded that Two-dose ivermectin prophylaxis at a dose of 300 μg/kg with a gap of 72 hours was associated 73% reduction of COVID-19 infection among healthcare workers for the following one-month
The study is currently under pre-print is yet to be peer-reviewed. This finding can be helpful in many cases where drugs like Hydroxychloroquine is contraindicated like certain cardiac conditions.
For further details click on the following link
https://www.medrxiv.org/content/10.1101/2020.10.29.20222661v1
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751